JP2023086719A - Ｃｄｋ４及び６阻害剤で以前に治療された患者におけるホルモン受容体陽性でヒト上皮成長因子受容体２陰性の進行性又は転移性乳がんの治療のためのフルベストラントとのｃｄｋ４及び６阻害剤の併用 - Google Patents

Ｃｄｋ４及び６阻害剤で以前に治療された患者におけるホルモン受容体陽性でヒト上皮成長因子受容体２陰性の進行性又は転移性乳がんの治療のためのフルベストラントとのｃｄｋ４及び６阻害剤の併用 Download PDF

Info

Publication number
JP2023086719A
JP2023086719A JP2022197331A JP2022197331A JP2023086719A JP 2023086719 A JP2023086719 A JP 2023086719A JP 2022197331 A JP2022197331 A JP 2022197331A JP 2022197331 A JP2022197331 A JP 2022197331A JP 2023086719 A JP2023086719 A JP 2023086719A
Authority
JP
Japan
Prior art keywords
cdk4
inhibitor
therapy
abemaciclib
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022197331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023086719A5 (https=
Inventor
モーガン リッチフィールド，レイシー
Morgan Litchfield Lacey
ギマラエス，クラウジア モラト
Morato Guimaraes Claudia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2023086719A publication Critical patent/JP2023086719A/ja
Publication of JP2023086719A5 publication Critical patent/JP2023086719A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022197331A 2021-12-10 2022-12-09 Ｃｄｋ４及び６阻害剤で以前に治療された患者におけるホルモン受容体陽性でヒト上皮成長因子受容体２陰性の進行性又は転移性乳がんの治療のためのフルベストラントとのｃｄｋ４及び６阻害剤の併用 Pending JP2023086719A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163288179P 2021-12-10 2021-12-10
US63/288,179 2021-12-10
US202263321218P 2022-03-18 2022-03-18
US63/321,218 2022-03-18

Publications (2)

Publication Number Publication Date
JP2023086719A true JP2023086719A (ja) 2023-06-22
JP2023086719A5 JP2023086719A5 (https=) 2025-11-06

Family

ID=85157124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022197331A Pending JP2023086719A (ja) 2021-12-10 2022-12-09 Ｃｄｋ４及び６阻害剤で以前に治療された患者におけるホルモン受容体陽性でヒト上皮成長因子受容体２陰性の進行性又は転移性乳がんの治療のためのフルベストラントとのｃｄｋ４及び６阻害剤の併用

Country Status (10)

Country Link
US (1) US20240398832A1 (https=)
EP (1) EP4444315A1 (https=)
JP (1) JP2023086719A (https=)
KR (1) KR20240118134A (https=)
AU (1) AU2022408062B2 (https=)
CA (1) CA3240454A1 (https=)
IL (1) IL313422A (https=)
MX (1) MX2024007015A (https=)
TW (1) TW202342044A (https=)
WO (1) WO2023107525A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251677T3 (es) 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
ATE412650T1 (de) 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
BRPI0716880A2 (pt) 2006-09-08 2013-10-15 Pfizer Prod Inc Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
SI2958916T1 (sl) 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
KR20180119570A (ko) * 2016-03-15 2018-11-02 메리맥 파마슈티컬즈, 인크. 항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료
CN115624552A (zh) 2017-05-02 2023-01-20 伊莱利利公司 用于乳腺癌的辅助治疗的内分泌疗法和abemaciclib组合
WO2021030248A1 (en) * 2019-08-12 2021-02-18 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant

Also Published As

Publication number Publication date
US20240398832A1 (en) 2024-12-05
AU2022408062B2 (en) 2025-08-14
CA3240454A1 (en) 2023-06-15
WO2023107525A1 (en) 2023-06-15
TW202342044A (zh) 2023-11-01
IL313422A (en) 2024-08-01
MX2024007015A (es) 2024-06-19
EP4444315A1 (en) 2024-10-16
AU2022408062A1 (en) 2024-06-20
KR20240118134A (ko) 2024-08-02

Similar Documents

Publication Publication Date Title
AU2019395093B2 (en) Methods for treating cancer resistant to CDK4/6 inhibitors
TW201410247A (zh) 醫藥組合
US20260041695A1 (en) Combination therapies for treatment of breast cancer
TW202120096A (zh) 使用包含atp競爭性akt抑制劑、cdk4/6抑制劑及氟維司群之組合療法治療乳癌
US20250319084A1 (en) Endocrine therapy and abemaciclib combination for the adjuvant treatment of node-positive, early stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
AU2018234903B2 (en) Combination therapies for the treatment of breast cancer
JP2020023497A (ja) 組合せ医薬
US20240173293A1 (en) Treatment of Breast Cancer with Amcenestrant and Palbociclib
AU2022408062B2 (en) Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor
EA051022B1 (ru) Ингибитор cdk4 и 6 в комбинации с фулвестрантом для лечения положительного по гормональному рецептору, отрицательного по рецептору 2 эпидермального фактора человека распространенного или метастатического рака молочной железы у пациентов, ранее получавших лечение ингибитором cdk4 и 6
TW202304438A (zh) 使用貝伐拉非尼及考比替尼或使用貝伐拉非尼、考比替尼及阿替利珠單抗的組合療法
CN118660706A (zh) Cdk4和6抑制剂与氟维司群组合用于在cdk4和6抑制剂先前治疗的患者中治疗激素受体阳性、人表皮生长因子受体2阴性晚期或转移性乳腺癌
CN118804747A (zh) 用安森司群治疗乳腺癌
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
HK40066922A (zh) 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251028